Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft-Reference-Cited by-同舟云学术

Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft

Published:2015-07-06 Issue:9 Volume:43 Page:1360-1371
ISSN:0090-9556
Container-title:Drug Metabolism and Disposition
language:en
Short-container-title:Drug Metab Dispos

Author:

Raub Thomas J.,Wishart Graham N.,Kulanthaivel Palaniappan,Staton Brian A.,Ajamie Rose T.,Sawada Geri A.,Gelbert Lawrence M.,Shannon Harlan E.,Sanchez-Martinez Concepcion,De Dios Alfonso

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmaceutical Science,Pharmacology

Reference68 articles.

1. Breast Cancer Resistance Protein and P-Glycoprotein in Brain Cancer: Two Gatekeepers Team Up

2. Function of the Blood-Brain Barrier and Restriction of Drug Delivery to Invasive Glioma Cells: Findings in an Orthotopic Rat Xenograft Model of Glioma

3. Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain

4. The restriction point of the cell cycle;Blagosklonny;Cell Cycle,2002

5. Comprehensive genomic characterization defines human glioblastoma genes and core pathways

Cited by 214 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prophylaxis with abemaciclib delays tumorigenesis in dMMR mice by altering immune responses and reducing immunosuppressive extracellular vesicle secretion;Translational Oncology;2024-09

2. GABAergic neuronal lineage development determines clinically actionable targets in diffuse hemispheric glioma, H3G34-mutant;Cancer Cell;2024-09

3. Mechanistic insights into medulloblastoma relapse;Pharmacology & Therapeutics;2024-08

4. CDKN2A/B Homozygous Deletion Sensitizes IDH-Mutant Glioma to CDK4/6 Inhibition;Clinical Cancer Research;2024-05-08

5. CDK4/6 inhibitors: The Devil is in the Detail;Current Oncology Reports;2024-05-07